3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
View Patent ↗Compounds of formula (I), in which R1, R2, R3, R4, R5, R6 and R7 have the meaning indicated in the description, are novel effective PDE4 inhibitors.
1. A compound of the formula I
in which
R1 is methoxy or difluoromethoxy,
R2 is methoxy difluoromethoxy or ethoxy,
R3 is hydrogen,
R31 is hydrogen,
R4 is hydrogen or acetyl,
R5 hydrogen,
R6 is cyano or cyclopropylmethoxy,
R7 is hydrogen or cyclopropylmethoxy, or a salt of this compound, an N-oxide of this compound, or a salt of an N-oxide of this compound.
2. A compound of the formula I as claimed in claim 1 , in which
R1 is methoxy,
R2 is methoxy,
R3 is hydrogen,
R31 is hydrogen,
R4 is hydrogen or acetyl,
R5 is hydrogen,
R6 is cyano or cyclopropylmethoxy,
R7 is hydrogen or cyclopropylmethoxy, or a salt of this compound, an N-oxide of this compound, or a salt of an N-oxide of this compound.
3. A compound of the formula I as claimed in claim 1 , in which
R1 is methoxy,
R2 is methoxy,
R3 is hydrogen,
R31 is hydrogen,
R4 is hydrogen or acetyl,
R5 is hydrogen,
R6 is cyclopropylmethoxy,
R7 is cyclopropylmethoxy, or a salt of this compound, an N-oxide of this compound, or a salt of an N-oxide of this compound.
4. A compound as claimed in claim 1 , selected from the group consisting of
(±)-acetic acid (3RS,4aRS,10bRS)-6-(3,4-bis-cyclopropylmethoxyphenyl)-8,9-dimethoxy-(1,2,3,4,4a,10b)-hexahydrophenanthridin-3-yl ester,
(±)-acetic acid (3SR,4aRS,10bRS)-6-(3,4-bis-cyclopropylmethoxyphenyl)-8,9-dimethoxy-(1,2,3,4,4a,10b)-hexahydrophenanthridin-3-yl ester,
(±)-(3RS,4aRS,10bRS)-6-(3,4-bis-cyclopropylmethoxyphenyl)-8,9-dimethoxy-(1,2,3,4,4a,10b)-hexahydrophenanthridin-3-ol,
(±)-(3SR,4aRS,10bRS)-6-(3,4-bis-cyclopropylmethoxyphenyl)-8,9-dimethoxy-1,2,3,4,4a,10b-hexahydrophenanthridin-3-ol,
(±)-acetic acid (3SR,4aRS,10bRS)-6-(4-cyanophenyl)-8,9-dimethoxy-(1,2,3,4,4a,10b)-hexahydrophenanthridin-3-yl ester,
(±)-4-((3SR,4aRS,10bRS)-3-hydroxy-8,9-dimethoxy-(1,2,3,4,4a,10b)-hexahydrophenanthridin-6-yl)-benzonitrile, and the salts of these compounds, the N-oxides of these compounds, and the salts of the N-oxides of these compounds.
5. A compound of the formula I according to claim 1 , in which the hydrogen atoms in positions 4a and 10b are in the cis position relative to one another, or a salt of this compound, an N-oxide of this compound, or a salt of an N-oxide of this compound.
6. A compound of the formula I according to claim 1 , which has with respect to the positions 4a and 10b, the configuration shown in the formula I*:
or a salt of this compound, an N-oxide of this compound, or a salt of an N-oxide of this compound.
7. A compound of the formula I according to claim 1 , which has with respect to the positions 3, 4a and 10b, the configuration shown either in formula I**, I*** or I****:
or a salt of this compound, an N-oxide of this compound, or a salt of an N-oxide of this compound.
8. A compound of the formula I according to claim 1 , which has with respect to the positions 3, 4a and 10b, the configuration shown in formula I*****:
or a salt of this compound, an N-oxide of this compound, or a salt of an N-oxide of this compound.
9. A pharmaceutical composition comprising one or more compounds of the formula I as claimed in claim 1 , or a pharmaceutically acceptable salt of this compound, a pharmaceutically acceptable N-oxide of this compound, or a salt of said N-oxide,together with a pharmaceutical auxiliary and/or excipient.